Our Facilities

I-40 Exit 104 Fiddler’s Run Morganton, NC 

2270 Hendersonville Rd Suite 1 Arden, NC

We proudly serve the Western North Carolina region and beyond with your privacy in mind. We have created a peaceful, comfortable, and positive environment for better treatment outcomes. Although we greatly prefer first contact to be a referral from your current mental health or primary care provider, we are happy to answer direct calls during our business hours Monday-Friday, 9:00am-5:00pm.Voicemail is available all other times, is frequently checked, and we will get back to you promptly. We will gladly and honestly tell you if our services are appropriate for your symptoms. Ketamine and Spravato (esketamine) nasal spray are not for everyone.

Welcome To Our Treatment Centers

A New Hope.  A New Era in Psychiatric Care.

Clinical studies have shown that ketamine and esketamine work to help those with treatment-resistant depression. These medications represent the dawn of a new era in psychiatric treatment. Let us help you break free from depression and associated anxiety.

Our Bays

Your privacy is important to us. We have created multiple treatment bays in a peaceful and relaxed environment with full medical observation and assistance.

We believe in your pursuit of happiness. Depression doesn’t have to last forever. Let us help.

What the experts say

Depression is common, and as many as one-third of people with depression are considered treatment resistant—not finding relief from symptoms even after trying several antidepressants. Ketamine and esketamine offer a new and fast-acting treatment for people that have not responded to other anti-depression medications. New research published May 2019 in the American Journal of Psychiatry supports the effectiveness and safety of Spravato (esketamine) nasal spray in treating depression for people who have not responded to previous treatments. This study is one of the key studies that led to the recent Food and Drug Administration (FDA) approval of esketamine nasal spray, in conjunction with an oral antidepressant, for use in people with treatment-resistant depression.

With most medications, like valium, the anti-anxiety effect you get only lasts when it is in your system. When the valium goes away, you can get rebound anxiety. When you take ketamine, it triggers reactions in your cortex that enable brain connections to regrow. It’s the reaction to ketamine, not the presence of ketamine in the body that constitutes its effects

John Krystal, MD, Chief Psychiatrist Yale Medicine

There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition. Controlled clinical trials that studied the safety and efficacy of this drug, along with careful review through the FDA’s drug approval process including a robust discussion with our external advisory committees, were important to our decision to approve this treatment.

Tiffany Farchione, MD, Director, Division of Psychiatry, US Food and Drug Administration

This trial of esketamine was one of the pivotal trials in the FDA's review of this treatment for patients with treatment resistant depression. Not only was adjunctive esketamine therapy effective, the improvement was evident within the first 24 hours. The novel mechanism of action of esketamine, coupled with the rapidity of benefit, underpin just how important this development is for patients with difficult to treat depression.

Michael Thase, MD, Penn Medicine, American Journal of Psychiatry